Breaking Medical Tech / Covid-19 Stock News: Reign Resources Corporation (OTCMARKETS: $RGNP) Announces Approval of Sigyn Therapeutics Merger
- Medical technology company focused on the treatment of life-threatening inflammatory conditions
- Jim Joyce, the Chairman and CEO of Sigyn Therapeutics was founder, Chairman and CEO of Aethlon Medical, (NASDAQ: $AEMD)
LOS ANGELES, CA - September 10, 2020 (Investorideas.com Newswire) Breaking Medical Tech/ Covid- 19 stock news - Reign Resources Corporation ("Reign") (OTCMARKETS: RGNP) announced today that the Company has approved a share exchange agreement with Sigyn Therapeutics, Inc., a privately held medical technology company focused on the treatment of life-threatening inflammatory conditions. As reported in a Schedule 14C Information statement filed today with the U.S. Securities and Exchange Commission (SEC) and a Form 8-K filed on August 31, 2020, Reign resources will acquire all of the outstanding capital stock of Sigyn Therapeutics in exchange for shares of Reign common stock representing approximately 75 percent of Reign's outstanding common stock. The Schedule 14C Information statement and Form 8-K can be accessed at www.SEC.gov.
Upon completion of the merger, Reign will be renamed Sigyn Therapeutics, Inc. and will be led by Sigyn co-founder Jim Joyce, who will serve as Chairman and CEO of the combined company. Sigyn Therapeutics will be focused on addressing a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome ("The Cytokine Storm" or "CSS") and not addressed with an approved therapy. The annual market opportunity for a therapeutic strategy to prevent or mitigate CSS has been reported to exceed $20 billion. Additional announcements regarding the combined company's management structure, Board of Directors and Science Advisory Board will be forthcoming.
Sigyn Therapy™ is a development-stage blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory conditions, including sepsis, which is the #1 cause of hospital deaths. The mechanism of Sigyn Therapy allows for a broad-spectrum of inflammatory targets to be depleted from the bloodstream. Among the targets are inflammatory cytokines, cytokine aggregates, endotoxin and CytoVesicles that transport cytokines and other inflammatory cargos.
Beyond sepsis, Cytokine Storm related therapeutic opportunities include, but are not limited to virus induced Cytokine Storm (a leading cause of COVID-19 deaths), bacteria induced Cytokine Storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy. Sigyn Therapy may also be a candidate to stabilize or extend the life of patients waiting for the identification of a matched liver for transplantation. In such a scenario, Sigyn Therapy™ would serve as a bridge-to-liver transplant. Cytokine Storm Syndrome can also result from trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies, cancer cachexia, acute kidney injury (AKI) and severe pneumonia.
Other Corporate Highlights
- Sigyn's co-founders have 50+ years of experience in the medical technology field and played instrumental roles in the development of three technologies that have been cleared by the FDA to treat COVID-19 infected individuals.
- Jim Joyce, the Chairman and CEO of Sigyn Therapeutics, has two decades of public company CEO and Board leadership experience. Specific to therapeutic blood purification, Mr. Joyce was the founder, Chairman and CEO of Aethlon Medical, (NASDAQ: AEMD) a company that he navigated from a single shareholder start-up to Nasdaq-traded Company with 8,000+ shareholders.
- Sigyn Therapy aligns with U.S. government initiatives to support broad-spectrum treatment countermeasures that mitigate life-threatening conditions resulting from pandemic outbreaks such as COVID-19.
- A deep pipeline of pre-clinical, clinical and regulatory milestones are planned over the next 12-18 months.
About Sigyn Therapeutics
Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy™ is a patent pending blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
About Reign Resources Corporation
Reign Resources Corp. is a Los Angeles-based, gold exploration company with a specific focus on the Bendigo & Ballarat regions in Victoria, Australia.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Reign Resources Corporation. ("Reign") that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "could," "will," "plan," "intend," "anticipate," "approximate," "expect," "potential," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Reign's future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Reign's expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Reign makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Reign's business and the price of the common stock of Reign, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Reign's business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity's ability to uplist to a national securities exchange, (viii) risks related to the combined entity's access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management's attention from Reign's ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Reign related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in "Risk Factors" and elsewhere in Reign's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Reign's views as of the date of this press release. Reign anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Reign's views as of any date subsequent to the date of this press release.
Contact Reign Resources Corporation
(213) 457 3772
Contact Sigyn Therapeutics, Inc.
Investorideas.com Paid news Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure : this news release featuring (OTCMARKETS: RGNP) is a paid for news release on Investorideas.com https://www.investorideas.com/News-Upload/
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com